The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective

Helmy M. Guirgis

Abstract

Background: The impact of programmed death receptor-ligand1 (PD-L1) on costs and value of the immune check point inhibitors (ICPI) has received minimal attention. Objectives: 1- Design a sliding scale to grade survival in 2nd-line non-small-cell lung cancer (NSCLC). 2- Compare costs and value of Nivolumab (Nivo), Atezolizumab (Atezo) and Pembrolizumab (Pembro) vs. Docetaxel (Doc).

Methods: Previously reported median overall survival (OS) and prices posted by parent company were utilized. The OS gains over controls in days were graded (gr) from A+ to D. Docetaxel costs were calculated for 6–12 cycles and the ICPI for 1 year. Adverse events treatment costs (AEsTC) were reported separately. The cost/life-year gain (C/LYG) was computed as drug yearly-cost/OS gain over control in days × 360 days. The relative value of the ICPI were expressed as $100,000/C/LYG.

Results: Costs of Doc 6 cycles were $23,868, OS/gr 87/C, AEs gr ¾ > 20%, AEsTC $1978 and 6–12 cycle C/LYG $98,764–$197,528. Nivo, Atezo and Pembro gr ¾ were < 20% at average costs of $1480. In non-squamous NSCLC, Nivo demonstrated OS/g 84/C and C/LYG $558,326 as compared with 264/A and $177,645 in PD-L1 > 10%. Atezolizumab OS/g were 87/B and C/LYG $551,407 improving in enriched PD-L1 to 162/A and $332,020 respectively. Pembrolizumab in PD-L1 > 1.0% demonstrated OS/g 57/C and C/LYG $659,059 improving in > 50% PD-L1 to 201/A and $186,897. PD-L1 enrichment increased RV of Nivo from 0.18 to 0.56, Atezo from 0.16 to 0.66 and Pembro from 0.15 to 0.53.

Conclusions: Simplified methodology to grade OS and weigh value of anticancer drugs was proposed. In 2nd-line non-squamous NSCLC, value of Doc, Nivo, Atezo and Pembro regardless of PDL-1 expression were limited and modest. Enrichment of PD-L1 resulted in unprecedented OS, improved grades and enhanced value at seemingly justifiable costs.
effectiveness however has received lesser attention. In the United States (US), an average cost-effectiveness ratio (ACER) of $100,000 has been generally accepted. Simplified methodology to weigh Nivo costs and value was recently described. The yearly-cost/life-year gain (C/LYG) were expressed relative to $100,000 [14, 15]. There is a compelling need for a simplified strategy to facilitate communication of drug outcome and value between medical professionals and patients. Our objectives were: 1-Grade survival gain over control in days 2-Weigh costs vs. value of Nivo, Atezo and Pembro in 2nd-line non-small-cell lung cancer (NSCLC). Docetaxel and Ramu were used as comparators.

Methods
Drug doses, frequency, OS gains over control and hazard ratios (HR) were quoted from previously published clinical studies. Prices and protocols were utilized as posted by the parent companies. Costs of Nivo 3.0 mg/Kg q 2w intravenously (iv), Doc 75 mg/m2 and Ramu 10 mg/Kg iv q 3 weeks were calculated for 70 Kg patients. Atezolizumab 1200 mg and Pembro 2.0, 10 mg/Kg and 200 mg iv were used q 3w. The OS gains in days were graded on a sliding scale as A+ for OS > 240 to D: < 60 days (Table 1). Adverse events-treatment costs (AEsTC) were reported separately. Docetaxel costs were calculated for 6–12 cycles and the ICPI for 1 year. Costs/life-year gain (C/LYG) were calculated as the drug yearly-cost /OS gain over control in days × 360 days. The relative values (RV) of the ICPI were expressed as $100,000/C/LYG.

Results
The OS gains in days by the evaluated drugs were graded on a sliding scale from A+ for OS > 240 to D < 60 days (Table 1). Review of safety of Doc [1] and Ramu/Doc combination [16] revealed AEs of > 20%. Both drugs carry black box warnings, a mechanism designed by the Federal Drug Administration (FDA) to communicate drug safety to patients.

Docetaxel
The estimated costs of Doc 6 cycles were $23,868, OS/gr 87/C at 6-12 cycle C/LYG $98,764 - $197,528. Based on pre-emptive use of colony stimulating agents and early recognition of peripheral neuropathy, the AEsTC of 6 cycles were $1978 increasing to $4840 for 12 cycles. Long-term treatment costs of delayed and chronic neuropathy were not considered.

The ICPI
In phase III trials of nivolumab vs docetaxel in previously treated NSCLC, all-grade AEs were less frequent with nivolumab than with docetaxel [4, 5]. Nivolumab, Atezo and Pembro were AEs gr ¼ < 20% [4–10]. In early 2016, the estimated median 4-week costs of the ICPI was $10,077 at a yearly cost of $131,001. The 4-week costs of Nivo 240 mg were later posted as $11,914, Atezo 1200 mg $11,493 and Pembro 200 mg $11,509. At 10 mg/Kg, the 4-week costs of Pembro were $40,135 and Nivo $33,063. Based on early recognition and preventive interventions, the yearly AEsTC did not differ from one ICPI to another and were estimated at $1978.

In Table 2, the OS/g of the squamous histology were 96/B and HR 0.59. The C/LYG was $488,524 and RV 0.20. In non-squamous, the OS/g were 84/C and HR of 0.73. The C/LYG was $558,326 and RV 0.18. There was no reported difference between squamous vs. non-squamous histology using Atezo or Pembro.

A summary of the impact of PD-L1 on OS/g and value in non-squamous NSCLC was shown in Table 3.

| Grade | OS in days |
|-------|------------|
| A+    | > 240      |
| A     | > 180–240  |
| B     | > 120–180  |
| C     | 60–120     |
| D     | < 60       |

Discussion
The present investigation was prompted by the rising costs of anti-cancer drugs, stagnant or diminishing value and widening gap in communication of cost and value issues between physicians and patients [20, 21]. Progress in drug development was achieved at high costs. The American Society of Clinical Oncology (ASCO) [17] and the European Society of Clinical Oncology (ESMO) [18] emphasized the role of value in the overall economic formulaire [19]. Our primary objectives were to design a grading system to measure OS and weigh costs vs. value of the ICPI in NSCLC. With the dropping out of Ramu from 2nd-line, Doc remained the only comparator.
Methodology
The unbiased and reliable OS endpoint was used throughout the present investigation. There is growing recognition among the oncology community that OS gains by anticancer drugs of < 2 months might not be clinically significant. In our study, grade D was assigned to < 60 days and A+ to > 240 days. Our goal was to facilitate full disclosure and transparency of outcome, costs and value to patients [20, 21]. The proposed methodology was not designed for medical economists but was rather geared towards the community oncologists. The simplicity of the grading system could enable oncologists, pharmacists and nurses to rapidly calculate drug value. The value was expressed relative to $100,000, the average acceptable ACER in the US. Admittedly, there are drawbacks limiting applications of the proposed methodology. Costs of hospitalization, drug administration, long-term treatment of chronic AEs and global QoL measures were not included. Fees for professionals including physicians, pharmacists and nurses were not considered. The methodology also failed to capture and capitalize on the longer duration of response of the ICPI over Doc.

Previously published methodology measuring differences in cost vs. outcome between 2 interventions [22, 23] could not be applied since in the present investigation 5 drugs were compared. Generic Doc costs were, not surprisingly much cheaper as compared with the ICPI. There was a non-significant cost difference between Nivo, Atezo and Pembro. The 4-week costs of Doc were $306, Nivo 240 mg $11,914, Atezo 1200 mg $11,493 and Pembro 200 mg $11,509. The incremental increase in cost per one-day OS gain was therefore used as the basis of our calculations. Costs, value, hazard ratios (HR) and median OS of Nivo at 12 months-milestone have recently been reported in a wide variety of cancer [15].

AEs
Docetaxel demonstrated AEs gr 3/4 of > 20%. The average AEsTC of 6 cycles were $1978 and 12 cycles $4940. The AEsTC could be burdensome and costly [24]. The cascade of neutropenia to febrile neutropenia, the non-hematological AEs and peripheral neuropathy have been well documented [1]. The gr ¾ AEs of the ICPI were generally < 10% [4–10]. The oral and iv steroids used for treatment of AEs were inexpensive. The costs of treatment represented an insignificant fraction of the total drug costs. With early use of scans and timely interventions, the average yearly AEsTC per patient treated by the ICPI were estimated at $1480. In CheckMate 017 in the squamous-NSCLC, the AEsTC of Nivo were $439 vs. docetaxel of $7024. In CheckMate 057 in non-squamous, Nivo AEsTC were $518, vs. Doc $5940 [25]. There has been widespread awareness of the potential hazards with continued gain in experience and management of AEs since the introduction of bevacizumab [26], Doc and the ICPI.

In our study, Nivo demonstrated discernible value improvement of the squamous over the non-squamous histology of the ICPI which showed OS difference between squamous- and non-squamous histology. Nivo, Atezo and Pembro demonstrated AEs gr ¾ of < 20%, maintained/or improved the QoL and carried no black box warnings. The adverse events treatment costs (AEsTC) represented a small and insignificant fraction of drug costs and were not included in drug costs. The C/LYG were weighed relative to $100,000. Relative values (RV) were computed as $100,000/C/LYG

### Table 2: Overall Survival and Value of Docetaxel and Ramucirumab in 2nd-line

| Nivo in 2nd-line | OS gains /Grade (OS/g & HR) | Costs | year-Costs | $C/LYG |
|------------------|-----------------------------|------|------------|--------|
| Generic docetaxel (Doc) 75 mg/m2 vs. supportive care [1] | 87/C HR not reported | $306 | 6 cycles: $23,868 | $98,764 |
| Ramucirumab (Ramu) + Doc vs. Doc, squamous and non-squamous, (REVEL) [16] | 42/D HR 0.86 | $933 | 12 cycles: $47,736 | $197,528 |

year-Costs = 4-week Costs of $306 x 13 weeks = $3978
year-Costs of 6 cycles = $3978 x 6 = $23,868
C/LYG yearly-cost/OS gain in days x 360 days
The costs of AEs treatment (AEsTC) were not included

### Table 3: Overall Survival and Value of Nivolumab

| Nivo in 2nd-line | OS gains /Grade (OS/g & HR) | C/LYG | Relative Values (RV) (100,000/LYG) |
|------------------|-----------------------------|------|----------------------------------|
| Nivolumab (Nivo) vs. Doc, squamous-NSCLC [4] | 96/C HR 0.59 P = 0.00025 | $488,524 | 0.20 |
| Nivo vs. Doc, non-squamous- NSCLC, CheckMate 057 [5] | 84/C HR 0.73 P = 0.0016 | $558,326 | 0.18 |
| Subset analysis in > 10% positive PD-L1 CheckMate 057 [5] | 264/A + HR 0.27 | $177,645 | 0.56 |

Nivolumab was tabulated separately since it was the only ICPI which showed OS difference between squamous- and non-squamous histology. Nivo, Atezo and Pembro demonstrated AEs gr ¾ of < 20%, maintained/or improved the QoL and carried no black box warnings. The adverse events treatment costs (AEsTC) represented a small and insignificant fraction of drug costs and were not included in drug costs. The C/LYG were weighed relative to $100,000. Relative values (RV) were computed as $100,000/C/LYG
histology. Atezolizumab and Pembro seemed to be equally effective irrespective of histology. Of interest, there is no documentation yet of benefit by PD-L1 enrichment in the squamous type. The latter is generally considered more homogenous with a higher incidence in non-smokers and males than the non-squamous.

Cost vs. value
The balance between drug costs and value is sensitive but elusive. The debate seems to continue [27]. Costs need to be maintained at certain levels for drug companies to proposer and keep their innovative edge. It is estimated that 1 billion dollars is spent to successfully bring a formula from the drawing boards to pharmacy shelves. Nonetheless, the price tags of 10 mg/Kg of Nivo and Pembro could dampen their use. The affordability of the ICPI in combination with other immune drugs e.g. Ipilimumab would be negatively impacted and curtailed using relatively high doses and frequent administrations. Such costs could be only tolerated if long-term disease control and/or cure are achieved.

The pendulum however has recently tipped in favor of value since ASCO and ESMO issued their initiatives in 2013 [17, 18]. The National Institute for Health and Care Excellence (NICE) in the United Kingdom stipulates that ACER interventions ought not to exceed 20,000–30,000 pounds per quality-adjusted life-year gained. Of note, Nivo approval by NICE is pending and negotiations are still continuing. It would be helpful to oncology professionals, patients, drug authorities and society if the FDA could give further guidance on value. At present, the US law prohibits discussion of drug costs during the approval process.

PD-L1 biomarker and drug value
In the early clinical studies of the ICPI in NSCLC various PD-L1 expression in tumor cells and infiltrating immune cells. At present, PD-L1 levels are being standardized and levels expressed as tumor proportion scores (TPS). There is up to 30% response in patients with PD-L1 enhanced expression. The findings of durable responses in non-enriched PDL-1 are indicative of the “imperfections” of PDL-1 marker. The tumor mutation load in combination with PDL-1, are emerging as more precise predictive markers [28]. The present study was the first to demonstrate that PDL-1 enrichment resulted in improved OS and enhanced value in NSCLC. The OS increase by PDL-1 enrichment was unexpected and unprecedented in an incurable disease as NSCLC. From an economic point of view, it would be prudent to spend upfront few hundred dollars on a reliable predictive marker or set of markers than to bear the costs of treating “all comers”. This strategy would spare the non-responders the high costs and unnecessary toxicity of ineffective therapy.

Duration of treatment
The ICPI treatment paradigm is evolving. The current recommendations on use of the ICPI are to continue treatment till AEs occurrence, progression or beyond progression. Costs and to a lesser extent AEs would increase with extended use. The duration of treatment comes down to a choice between cost vs. value and is presently an area of active investigation. It remains to be seen whether the incremental survival benefit by prolonged use ICPI could justify the additional yearly costs of $131,000.

Policies and perspectives
The FDA has recently adopted a new trend of approval of new drugs based on early endpoints other than survival. The present methodology could be modified to use disease control rates and other endpoints after

### Table 4

| Drug and setting | OS gains in days/Grade(OS/g) & HR | C/LYG | RV |
|------------------|----------------------------------|------|----|
| **Atezolizumab (Atezo) vs. Doc irrespective of PD-L1, vs. Doc (phase II, POPLAR) [8]** | 87/C HR 0.73 | $618,244 | 0.16 |
| **Atezo, low or undetectable PD-L1 vs. Doc, Phase III OAK [9, 10]** | 111/C HR 0.75 | $475,265 | 0.20 |
| **Atezo, PD-L1 > 1.0% tumor cells (TC) or in tumor-infiltrating immune cells (IC) vs. Doc [10]** | 162/B HR 0.74 | $325,644 | 0.30 |
| **Atezo, PD-L1, TC or IC > 5% vs. Doc, [10]** | 165/B | $319,974 | 0.31 |
| **Atezo, PD-L1 > 50% or IC > 10% vs. Doc** | 34/A + HR 0.41 | $151,193 | 0.66 |
| **Pembrolizumab (Pembro) PD- L1 > 1.0% positive vs. Doc KEYNOTE – 010 [7] Subset analysis** | 57/D HR 0.71 | $659,059 | 0.15 |
| **Pembro 10 mg/Kg, PD-L1 1.0% positive, KEYNOTE – 010** | 126/B HR 0.61 | $1,490,729 | 0.07 |
| **Pembro 2.0 mg/Kg, > 50% positive KEYNOTE – 010** | 201/A HR 0.54 | $186,897 | 0.53 |

*The average OS gains of Atezo in the POPLAR and OAK were 99 days at C/LYG of $551,407 and RV 0.19*
adjustments with appropriate correction factors. Higher doses and longer duration of treatment by costly drugs need to be scrutinized before utilization.

In 2nd-line non-mutated NSCLC, the superiority of ICPI over chemotherapy has been generally accepted despite concerns on cost issues. Costs of Nivo and Pembro were described by Salts [29] as thousands of times the cost of gold.

In 1st-line, Pembro in combination with pemetrexed and carboplatin without PD-L1 enrichment has recently demonstrated higher response rates with deeper and longer duration of response [30]. The overall survival data have not yet matured. Clearly, PD-L1 is not the whole story. Tumor mutation burden can be used as well to decide on immunotherapy approaches [31]. Enthusiastic use of the ICPI however needs to be tempered by the economic pressures of countries and patients with limited resources. With the upcoming waves of generic chemotherapeutic drugs including pemetrexed, the role of Doc and many others is not yet dead but just diminished [32].

Conclusions
Simplified methodology to grade OS and weigh value vs. costs of anticancer drugs was proposed for community oncologists. The results suggested that value and costs were essential in securing a fair and equitable economic balance between consumers and drug companies. Doc demonstrated distinct cost and value advantages. Its AEs and impaired QoL were serious impediments. In 2nd-line, value of Nivo, Atezo and Pembro regardless of PDL-1 expression were rather limited and modest. Enrichment of PDL-1 resulted in unprecedented OS, improved grades and enhanced value at seemingly justifiable costs. The consistency of our results could give credence to the conclusions. The non-uniform testing of PDL-1 testing, subset analysis and scanty available comparative data precluded favoring one ICPI over the other.

Abbreviations
ACER: Average cost-effectiveness ratio; AEs: Adverse events; AEsTC: Adverse events treatment costs; Atezo: Atezolizumab; C/LYG: Cost/Life-year gain; CI: Confidence Interval; EGFR: Epidermal growth factor receptor; FDA: Federal Drug Administration; Gr: Grade; HR: Hazard Ratio; ICPI: Immune check point inhibitors; Nivo: Nivolumab; NSCLC: Non-small-cell lung cancer; OS: Overall survival; PD-1: Program death protein 1; PD-L1: Programmed death receptor-ligand 1; Pembro: Pembrolizumab; QoL: Quality of Life; Ramu: Ramucirumab; RV: Relative values; TPS: Tumor Proportion Score

Acknowledgements
Sincere thanks to Corey J. Langer, MD, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA for valuable insight and support. The author is grateful to Robert Townley, MD, Professor of Medicine, Creighton Medical School, Omaha, Nebraska, for helping me be the first medical student in the PHD-MD program.

Funding
I funded the whole project. There was no outside source.

Authors’ contributions
I contributed 100% to the project, I am the only author.

Ethics approval and consent to participate
Not applicable

Consent for publication
I consent.

Competing interests
The author declares that he has no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 20 October 2017 Accepted: 18 January 2018
Published online: 20 February 2018

References
1. Shepherd FA, Dancey J, Ramilau R, et al. Prospective randomized trial of Docetaxel versus best supportive Care in Patients with non–small-cell lung cancer previously treated with Platinum-Base chemotherapy. J Clin Oncol. 2000;18:2095–103.
2. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50.
3. Moa TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.
4. Brahmer J, Reckamp KL, Bazz P, et al. Nivolumab versus Docetaxel in advanced Squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35.
5. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39.
6. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non–small cell lung cancer. N Engl J Med. 2015;372:2018–28.
7. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet. 2016;387:1540–50.
8. Fehrenbacher L, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicenter, open-label, phase 2 randomized controlled trial. Lancet Oncol. 2016;17:1285–97.
9. Barlesi F, Park K, Cardiello F, et al. Primary analysis from OA1, a randomized phase III study comparing atezolizumab with docetaxel in advanced NSCLC: ESMO Congress. Abstract LBA 44; 2016.
10. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):295–305. https://doi.org/10.1016/S0140-6736(16)32517-3.
11. Reck M, Rodriguez-Arreb D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:223–33.
12. Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for first line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34:2983–93.
13. Rizvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34:2969–79.
14. Guirgis HM. Value of anticancer drugs in castrate-resistant metastatic prostate cancer, economic tools for the community oncologist. JCSO. 2015;13:362–6.
15. Guirgis HM. Costs and Values of Nivolumab in Advanced/Metastatic Cancer, cancer science and research, symbolsonline.org. 2017;DOI:1–3. http://dx.doi.org/10.15256/croa.2017.00131.
16. Garon EB, Ciuleanu TE, Arienti G, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non–small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:1994–2005.
17. Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology statement: a framework to assess the value of cancer treatment options. J Clin Oncol. 2015;22.
18. Cherny NI, Sullivan R, Dafni U, et al. A standardized, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies. The European Society for Medical
19. Raghavan D. The value proposition in oncology: ASCO and ESMO bite the bullet. Editorial, HemOnc today 25 Sept 2015.
20. Henrikson NB, Shankaran V, et al. Improving price transparency in cancer care. J Oncol Pract. 2016;12:44–7. https://doi.org/10.1200/JOP.2015.006171.
21. Ubel PA, Abernethy AP, Zafar SY. Perspective, full disclosure—out of pocket costs as side effects. N Engl J Med. 2013;369(1484–1486) https://doi.org/10.1056/NEJMp130.
22. Russell LB, Gold MR, Siegel JE, et al. Panel on cost-effectiveness in health and medicine. The role of cost-effectiveness analysis in health and medicine. JAMA. 1996;276(14):1172–7.
23. Siegel JE, Weinstein MC, Russell LB, et al. Panel on cost-effectiveness in health and medicine. Recommendations for reporting cost effectiveness analyses. JAMA. 1996;276(16):1339–41. Credit: Wikimedia CC-BY-SA-3.0
24. Niraula S, Amir E, Vera-Badillo F, et al. Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. J Clin Oncol. 2014;32:3634–42. https://doi.org/10.1200/JCO.2016.34.15_suppl.6617
25. Venkataraman M. Estimated costs of managing treatment-related adverse events (TREAs) of nivolumab in the Checkmate 017 and CheckMate 057 phase III non-small-cell lung cancer (NSCLC) trials. Journal of Clinical Oncology 34, no. 15_suppl (May 2016) 6617-6617.
26. Ranpura V, Hapani S, Wu S, et al. Treatment-related mortality with Bevacizumab in cancer patients: a meta-analysis. JAMA. 2011;305:847–94.
27. Saltz LB. The value of considering cost, and the cost of not considering value. JCO. 2015;34:659–60.
28. Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med 2017; 377:849-861. August 31, 2017. https://doi.org/10.1056/NEJMra1703413.
29. Saltz LB. Perspective on value in cancer care. Chicago: Plenary session, ASCO Annual meeting; 2015.
30. Langer CJ, Gadgeel SM, Borghaei H, et al. Randomized phase 2 study of Carboplatin and Pemetrexed ± Pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G. Lancet Oncol. 2016;17(11):1497–1508. https://doi.org/10.1016/S1470-2045(16)30498-3
31. Rizvi N. In patients with non-small cell lung cancer, tumor mutation load emerging as biomarker for immunotherapy. The ASCO Post 8, issue 21: 11, 2017.
32. Herbst RS, Szol ov M. Diminished but not dead: chemotherapy for the treatment of NSCLC. Lancet Oncol. 2016;17:1464–5.